The CEO of STXPC, Dr. Cardelli, will present a talk entitled “High Content Imaging Screens to Discover Repurposed Drugs that Impact IPF”. Other speakers will include representatives from Gilead, Genentech, Bristol-Myers Squib and other leading companies and academic institutions focused on finding cures for this devastating disease.
News and updates about Segue Therapeutics
Dr. Nick Dulin, as research investigator at the University of Chicago, has accepted the appointment of CSO for STXPC. Dr. Dulin is a leader in researching the mechanisms that are involved in fibrosis and discovering new drugs that block this pathological process. He will lead the team to complete preclinical animal studies and other IND-enabling studies for the repurposed drugs, positioned to enter clinical trials in the next year.
A new private molecular biology drug discovery laboratory is scheduled to open on August 1, 2017 at InterTech1 in Shreveport Louisiana. The laboratory was co-founded by Dr. James Cardelli, PhD (founder of STXPC, STX and SSM) and a former PhD student Dr. Alana Gray. SSL secured investment from a private source and is partially owned by STX. The laboratory will support research projects funded by STX and STXPC and will perform contract research for Universities and biotechnology companies.
SegueTx-Pancreatic Cancer, LLC is one of four finalists in the 5th Annual Louisiana BioChallenge in which Louisiana life sciences startups compete for more than $50,000 in prizes. The final pitch event hosted by the New Orleans BioInnovation Center is November 16 at the Joy Theater on Canal Street.
SegueTx-Pancreatic Cancer, LLC was named a semifinalist for the Louisiana 5th Annual BioChallenge Pitch Competition organized by the New Orleans BioInnovation Center. If the company's pitch to the judges is successful, STX founder Jim Cardelli, Ph.D., will pitch in the finals to be held in November at the Joy Theater in New Orleans. The winner receives up to $50,000 in cash and prizes.
Segue Therapeutics, LLC is happy to announce that Imre Noth, M.D., Professor and Director of Interstitial Lung Disease at The University of Chicago Medicine, has agreed to join STX as a clinical advisor. Dr. Noth will be a tremendous asset in the development and implementation of clinical trials to test the ST2000 series of repurposed drugs that could impact idiopathic pulmonary fibrosis, a devastating disease that affects 200,000 people annually in the U.S.
Segue Therapeutics subsidiary company SegueTx-Pancreatic Cancer, LLC received an investment from the New Louisiana Angel Fund 1, LLC.
Segue Therapeutics, LLC was recognized as a high-growth startup by the Entrepreneur Accelerator Program (EAP) at the August 16, 2016, unveiling of their Wall of Entrepreneurial Achievement. Segue Therapeutics was recognized as one of thirteen portfolio companies so far established in Caddo Parish that received EAP services, demonstrated solid business plans, and received capital investment from local accredited investors. Companies that achieved space on this Wall of Entrepreneurial Achievement are working toward growth that will help diversify the northwest Louisiana economy.
STX is proud to announce that Dr. Sami Nazzal, a professor at the University of Louisiana at Monroe, has agreed to become a company scientific advisor. Dr. Nazzal is a formulation and drug product development scientist. He will assist the company in its effort to develop viable and patentable formulations for pre-clinical and clinical testing.
STX is happy to announce that Michael Hetzel has agreed to become a company advisor. Mr. Hetzel brings a diverse business background, including manufacturing CEO, international trade specialist and business broker.
Segue Therapeutics is pleased to announce that Ron Ondechek has agreed to become one of the company's business advisors. Mr. Ondechek is an operations focused executive with more than 15 years of experience as a board member, fund manager and entrepreneur.
The New Louisiana Angel Fund pledged investments totaling $170K to SegueTx-Pancreatic Cancer, a subsidiary company of Segue Therapeutics. The seed funding round will close upon capital investments of $500K.
The Company was voted into the final five contestants in the third annual Louisiana Start Up Prize, an international competition to choose the best newly launched company. The winner of the competition, selected from over 100 participating companies, was Banten Labs for developing novel gaming software to aid people with disabilities.
We are proud to announce that Erkut Borazanci, M.D. has agreed to become the first clinical science advisor at the company. He was trained at LSUHSC-S where he received a Master's Degree in Biochemistry and Molecular Biology and an M.D. He is a practicing oncologist at HonorHealth in Scottsdale, Arizona and has been a principal investigator on 26 clinical trials. Data from a recent Phase I trial suggests that combination therapy could be efficacious against pancreatic cancer, a devastating disease that claims the lives of 40,000 Americans every year.
The paper titled Zinc finger E-box binding homeobox-1 (Zeb1) drives anterograde lysosome trafficking and tumor cell invasion via upregulation of Na+/H+ Exchanger-1 (NHE1) by Dykes et. al. has been accepted for publication by the journal Molecular Carcinogenesis. This paper concludes that lysosome trafficking in cells that have undergone epithelial-to-mesenchymal transition plays a major role in the ability of these tumor cells to invade leading to metastasis. This information further supports the company’s premise that targeting lysosome trafficking is a promising therapeutic approach to slow the progression of invasive cancers.
SegueTx-Pancreatic Cancer announces the opening of a seed round of capital raising. This round will be open until we reach the goal of $500,000 in cash investments.
SegueTx-Pancreatic Cancer is excited about the recent publication by the founder and members of his laboratory at LSUHSC entitled The Arf-like GTPase Arl8b is essential for three-dimensional invasive growth of prostate cancer in vitro and xenograft formation and growth in vivo. This article appears in OncoTarget, volume 7, number 21.
This paper adds to the growing body of data validating lysosome trafficking as a good cancer therapeutic target and adds value to the repurposed drugs discovered that prevent lysosome exocytosis and inhibit tumor cell invasion.